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Accepted 12 August 2015We report a 20-year-old female with generalized, severe, recessive dystrophic epidermolysis bullosa who
developed secondary chronic anal ﬁssures. This resulted in anal sphincter spasm and severe, disabling pain.
She was treated with ﬁve botulinum toxin A injections into the internal anal sphincter over a period of 2 years
and gained marked improvement in her symptoms. This case demonstrates the successful use of botulinum
toxin A injections to relieve anal sphincter spasm and ﬁssuring, with long-term improvement.
© 2015 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
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Epidermolysis bullosa (EB) consists of a heterogeneous group of rare
autosomal dominant or recessive disorders, characterized by epithelial
fragility. Patients with recessive dystrophic epidermolysis bullosa
(RDEB) often develop chronic constipation caused by painful defecation
from blistering and tearing due to skin fragility, as well as by poor
motility from opioid analgesia, which is frequently used in those with
severe EB. As a result of straining, anal ﬁssuring may further develop.
Due to these painful ﬁssures and ongoing constipation, chronic anal
ﬁssures and anal sphincter spasmmay result. An anal ﬁssure is a tear in
the anoderm (squamous epithelium) distal to the dentate line. By
deﬁnition, an acute anal ﬁssure heals within 6 weeks with conservative
local management, whereas a chronic anal ﬁssure fails conservative
management, requiring more aggressive measures.
This case demonstrates the successful use of botulinum toxin type
A (BTX-A) to relieve anal sphincter spasms and improve chronic anal
ﬁssures from EB.
Case report
A 20-year-old female with generalized, severe RDEB gradually
developed chronic anal ﬁssures, resulting in severe anal sphincter
spasms and severe, disabling pain. She also described chronic(C. Chaptini).
er Inc. on behalf of Women's Derconstipation and hemorrhoids. Her quality of life (QOL) was greatly
diminished by this symptom (QOLEB pilot score of 42/75; Frew et al.,
2009). She became profoundly depressed due to the pain and
apparently insoluble problem.
She was born to nonconsanguineous parents and was diagnosed
with RDEB as an infant. She had inherited two heterozygous deletion
mutations in the COL7A1 gene, c[4918del] in exon 52 and [7634del] in
exon 102, predicting two frameshift mutations, p. [Gly1640fs] and
[Gly2545fs], leading to presumed downstream premature termina-
tion codons (Venugopal et al., 2013). This explained the lack of
collagen VII expression in her skin on immunoﬂuorescence mapping.
Blistering was extensive from early infancy, causing cutaneous
scarring and mitten deformities of hands and feet. She developed
known complications of EB, including squamous cell carcinoma,
hepatic amyloidosis (Chaptini et al., 2015), premature and extensive
dental caries, esophageal strictures, osteoporosis, hypogonadotrophic
hypogonadism, and bilateral inferior exposure keratopathy. Previous
procedures included surgeries to correct hand contractures, right
lower-lid ectropion repair, and regular iron and blood transfusions
for anemia. Medications included long-standing phenytoin 50 mg
three times daily to aid wound healing, pantoprazole, cholecalciferol,
estradiol/norethisterone, pregabalin, tramadol, oxycodone,
and lactulose.
Physical examination revealed circumferential anal ulceration and
an anal ﬁssure at 6 o’clock. Internal hemorrhoids were present.
Investigations revealed normochromic anemia (hemoglobin 85 g/L),
hyponatremia (132 mmol/L), hypoalbuminemia (21 g/L), creatininematologic Society. This is an open access article under the CC BY-NC-ND license
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picture. Anal manometry showed resting pressure 64 cmH2O (range:
54-104), reduced squeeze pressure 147 cmH2O (range: 179-317), and
sphincter length 3.5 cm (range: 2.5-5).
Conservative measures for her anal ﬁssures were trialed without
success, including laxatives and a high-ﬁber diet. Glyceryl trinitrate
0.2% ointment and zinc barrier were also unsuccessful. When she was
referred in November 2008 for participation in a cell therapy clinical
trial in Sydney in 2009 (Venugopal et al., 2013), we were asked about
how tomanage theﬁssuring. After topical tacrolimus failed to relieve any
inﬂammation, the suggestionwasmade to consider intramuscular BTX-A
as a therapeutic intervention. Over a period of 2 years starting from age
19 years, she underwent ﬁve BTX-A injections into the internal anal
sphincter (one injection approximately every 5months), performed by a
colorectal surgeon. In each case, a general anesthetic was used, and 50
units of BTX-A in 2.5 mL of normal saline were injected into the internal
anal sphincter in all four quadrants. No complications or adverse effects
were experienced. The patient experienced a 50% subjective improve-
ment in her pain and spasms for at least 1 month after each injection,
followed by residual improvement formanymonths. Four years after the
cessation of injections, the patient’s symptoms were still improved from
baseline. She did not experience any fecal incontinence.
Discussion
Chronic anal ﬁssures often complicate RDEB, as these patients
develop constipation early on in life because of anal discomfort and
medications. Once the tear in the anusmucosa occurs, it begins a cycle
leading to repeated injury. The exposed internal sphincter muscle
underneath the tear goes into spasm. As well as causing severe pain,
the spasm pulls the edges of the ﬁssure apart, impairing wound
healing. The spasm also causes further tearing of the mucosa with
each following bowel motion. In this case, BTX-A injections success-
fully relieved the anal sphincter spasm and pain secondary to
recurrent anal ﬁssures by interrupting the cycle of repeated injury.
Botulinum toxin, produced by Clostridium botulinum, blocks cholin-
ergic nerve terminals and inhibits release of acetylcholine from nerve
endings. It has been used to successfully treat certain spastic disorders of
skeletalmuscle, suchasblepharospasmand torticollis, aswell aswrinkles
and spastic contractures in cerebral palsy.
Although there have been no documented cases of its use in EB for
anal sphincter spasmorﬁssuring, it is commonly used to treat idiopathic
anal sphincter spasm, typically given as injections around the anal canal
(10 to 100 units total). It has also been reported to improve healing in
patientswith chronic analﬁssures (Maria et al., 1998b). Despite variable
doses and locations of the injection, four high-quality studies report its
efﬁcacy (Brisinda et al., 2004, 2007; Jost and Schrank, 1999; Maria et al.,
1998a; Mínguez et al., 1999). The healing rate appears to be related to
the dose and probably to the number of puncture sites (Maria et al.,
1998a; Mínguez et al., 1999). In a randomized controlled trial, where
100 patients were treated with either BTX into the internal anal
sphincter or 0.2% nitroglycerin ointment for 8weeks, after 2months the
ﬁssures were healed in 46 (92%) of 50 patients in the BTX group and
in 35 (70%) of 50 in the nitroglycerin group (p=0.009). Three patients
in the BTX group reported adverse effects (p b 0.001) from mild
incontinence to ﬂatus that lasted 3 weeks after treatment but
disappeared spontaneously (Brisinda et al., 2007). In another random-
ized controlled trial, 50 patients with chronic anal ﬁssures received
injections of 50 units of Botox formulation (group I), and 50 patients
received injections of 150 units of Dysport toxin (group II; Brisinda et al.,
2004). After 2 months, 46 patients in group I and 47 patients in group II
had ahealed scar. In group I patients, themean restinganal pressurewas
41.8% lower and the maximum voluntary squeeze pressure was 20.2%
lower than the baseline value. In group II patients, the resting analpressure and maximum voluntary squeeze pressure were 60.0 ± 12.0
mmHg and 71.0 ± 30.0 mmHg, respectively. There were no relapses in
the 21 months of follow-up (Brisinda et al., 2004). Similarly, in a study
where 30 patients with chronic anal ﬁssures were randomized to
intra-sphincteric BTX-A or saline injection, after 2 months signiﬁcantly
more patients who had received BTX-A had healed (73% versus
13%; Maria et al., 1998a). This was supported by another study where
repeated BTX-A therapy was used in 50 patients who failed initial
(insufﬁcient) BTX-A treatment. Nineteen of 20 patients (95%) treated
with ﬁve units of BTX-A were pain-free within 1 week, and healing was
observed in 70% by 3 months. Twenty-two of 30 patients (73%) treated
with 10 units of BTX-A were pain-free within 1 week, and 19 (63%)
demonstrated healing after 3 months (Jost and Schrank, 1999).
Botulinum toxin injections have been used twice before in patients
with EB in the literature for reasons other than anal sphincter
spasm. BTX-A has been used to treat palmar and plantar hyperhidro-
sis, which was found to be effective and safe (Schnider et al., 1997;
Vadoud-Seyedi, 2004). As hyperhidrosis contributes to frictional
trauma and the development of blisters in EB simplex (EBS), it was
thought that BTX-A may have a therapeutic role in this condition.
Hence, BTX-A was used in a double-blinded-study of a 43-year-old
woman with EBS, localized type, to treat blisters and erosions on the
plantar aspect of her feet (Abitbol and Zhou, 2009). The foot treated
with BTX-A had decreased pain and perspiration and a 64% decrease
in blister formation after 3 months compared to the control foot,
which received normal saline injections (Abitbol and Zhou, 2009).
Furthermore, a retrospective study of 14 patients (6 with EBS) with
foot blisters who had received botulinum toxin therapy showed that
13 (93%) patients reported reduced blistering and pain, with a mean
effect of 3 months (Swartling et al., 2010). The mechanism of action of
BTX-A in the above cases is via blocking the autonomic cholinergic
junctions of the post-ganglionic sympathetic ﬁbers to the sweat
glands, thus preventing hyperhidrosis.
The mechanism of action in improving chronic anal ﬁssures and
spasm, as depicted in this case, is likely mainly due to cholinergic
nerve terminal blockade, preventing spasm, as well as blockade of
the post-ganglionic sympathetic ﬁbers, preventing sweating, and subse-
quent ﬁssuring.
The main adverse effects after local injection of BTX-A are
weakness in the muscles adjacent to the treatment sites and, in the
perianal area, fecal incontinence. Beneﬁcial effects have been shown
to last from 4 months to 1 year (Swartling et al., 2010). The long-term
outcome of BTX-A treatment has not been well described in the
literature; recurrence may be common. The report with the longest
follow-up (42 months) showed that in 57 patients who had healed
anal ﬁssures from BTX 6 months after injection, a recurrent ﬁssure
was observed in 22 patients (42%; Minguez et al., 2002). However, in
the case described, long-termbeneﬁts remained after 4 years, indicating
that this is a useful adjunctive treatment for rare patients with these
disabling symptoms.
Conclusion
This case demonstrates the successful treatment of chronic anal
ﬁssures and anal sphincter spasm with botulinum toxin A injections,
with nil adverse effects. Botulinum toxin A injections should be
considered as a treatment for anal sphincter spasm secondary to
recurrent anal ﬁssures in EB when conservative measures fail.
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